Podium to Practice: ESMO® 2025 – Melanoma: High-risk laBCC and lacSCC Patients

Podium to Practice: ESMO® 2025 – Melanoma: High-risk laBCC and lacSCC Patients

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Teresa Petrella

Icon Chair Speaker

Speakers

Dr. Marcus Butler

Dr. Caroline Robert

Studies / Trials Discussed

LBA60 – Favorable activity and safety of intralesional L19IL2/L19TNF in high-risk laBCC and lacSCC patients

Studies/trials discussed:

LBA60 – Favorable activity and safety of intralesional L19IL2/L19TNF in high-risk laBCC and lacSCC patients
Tagged